{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:19:55Z","timestamp":1793272795290,"version":"4.5.0"},"reference-count":136,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>With the advent of PET imaging in 1976, 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-PET became the preferred method for in vivo investigation of cerebral processes, including regional hypometabolism in Alzheimer\u2019s disease. With the emergence of amyloid-PET tracers, [11C]Pittsburgh Compound-B in 2004 and later [18F]florbetapir, [18F]florbetaben, and [18F]flumetamol, amyloid-PET has replaced FDG-PET in Alzheimer\u2019s disease anti-amyloid clinical trial treatments to ensure \u201camyloid positivity\u201d as an entry criterion, and to measure treatment-related decline in cerebral amyloid deposits. MRI has been used to rule out other brain diseases and screen for \u2018amyloid-related imaging abnormalities\u2019 (ARIAs) of two kinds, ARIA-E and ARIA-H, characterized by edema and micro-hemorrhage, respectively, and, to a lesser extent, to measure changes in cerebral volumes. While early immunotherapy trials of Alzheimer\u2019s disease showed no clinical effects, newer monoclonal antibody trials reported decreases of 27% to 85% in the cerebral amyloid-PET signal, interpreted by the Food and Drug Administration as amyloid removal expected to result in a reduction in clinical decline. However, due to the lack of diagnostic specificity of amyloid-PET tracers, amyloid positivity cannot prevent the inclusion of non-Alzheimer\u2019s patients and even healthy subjects in these clinical trials. Moreover, the \u201cdecreasing amyloid accumulation\u201d assessed by amyloid-PET imaging has questionable quantitative value in the presence of treatment-related brain damage (ARIAs). Therefore, future Alzheimer\u2019s clinical trials should disregard amyloid-PET imaging and focus instead on assessment of regional brain function by FDG-PET and MRI monitoring of ARIAs and brain volume loss in all trial patients.<\/jats:p>","DOI":"10.3233\/jad-240206","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T10:53:34Z","timestamp":1729248814000},"page":"S579-S601","source":"Crossref","is-referenced-by-count":13,"title":["PET\/CT\/MRI in Clinical Trials of Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7420-2367","authenticated-orcid":false,"given":"Poul F.","family":"H\u00f8ilund-Carlsen","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge R.","family":"Barrio","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-240206_ref1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1468-1331.2010.03040.x","article-title":"EFNS guidelines for the diagnosis and management of Alzheimer\u2019s disease","volume":"17","author":"Hort","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-240206_ref7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1468-1331.2012.03784.x","article-title":"EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia","volume":"19","author":"Sorbi","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-240206_ref8","doi-asserted-by":"crossref","first-page":"e1538","DOI":"10.1212\/WNL.0000000000010256","article-title":"Multitracer model for staging cortical amyloid deposition using PET imaging","volume":"95","author":"Collij","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-240206_ref9","doi-asserted-by":"crossref","first-page":"e1692","DOI":"10.1212\/WNL.0000000000200148","article-title":"Spatial-Temporal patterns of \u03b2-amyloid accumulation: A subtype and stage inference model analysis","volume":"98","author":"Collij","year":"2022","journal-title":"Neurology"},{"key":"10.3233\/JAD-240206_ref10","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240206_ref11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240206_ref12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaneurol.2024.1612","article-title":"Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairment","volume":"81","author":"Groot","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240206_ref13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref14","unstructured":"Alzforum, Revised Again: Alzheimer\u2019s Diagnostic Criteria Get Another Makeover. Revised AgaAlzheimer\u2019s Diagnostic Criteria Get Another Makeover (2023, accessed 14 June 2024)."},{"key":"10.3233\/JAD-240206_ref15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fpsyt.2019.00924","article-title":"Current challenges in translational and clinical fMRI and future directions","volume":"10","author":"Specht","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.3233\/JAD-240206_ref16","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/s42003-023-05629-w","article-title":"Mapping and comparing fMRI connectivity networks across species","volume":"6","author":"Pagani","year":"2023","journal-title":"Commun Biol"},{"key":"10.3233\/JAD-240206_ref17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0140-6736(66)92199-4","article-title":"The luxury-perfusion syndrome and its possible relation to acute metabolic acidosis localised within the brain","volume":"2","author":"Lassen","year":"1966","journal-title":"Lancet"},{"key":"10.3233\/JAD-240206_ref18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1152\/japplphysiol.00276.2018","article-title":"No evidence for direct effects of recombinant human erythropoietin on cerebral blood flow and metabolism in healthy humans","volume":"125","author":"Henriksen","year":"1985","journal-title":"J Appl Physiol"},{"key":"10.3233\/JAD-240206_ref19","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.neurobiolaging.2012.09.011","article-title":"The capillary dysfunction hypothesis of Alzheimer\u2019s disease","volume":"34","author":"\u00d8stergaard","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-240206_ref20","doi-asserted-by":"crossref","first-page":"119284","DOI":"10.1016\/j.neuroimage.2022.119284","article-title":"Deuterium metabolic imaging and hyperpolarized 13C-MRI of the normal human brain at clinical field strength reveals differential cerebral metabolism","volume":"257","author":"Kaggie","year":"2022","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-240206_ref21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-003-0643-x","article-title":"Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug development","volume":"59","author":"Bergstr\u00f6m","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.3233\/JAD-240206_ref22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40658-020-00290-2","article-title":"State of the art in total body PET","volume":"7","author":"Vandenberghe","year":"2020","journal-title":"EJNMMI Phys"},{"key":"10.3233\/JAD-240206_ref23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00259-005-0038-6","article-title":"How few cancer cells can be detected by positron emission tomography? A frequent question addressed by anstudy","volume":"33","author":"Fischer","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240206_ref24","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1007\/s00259-019-04383-8","article-title":"Global disease score (GDS) is the name of the game!","volume":"46","author":"H\u00f8ilund-Carlsen","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240206_ref25","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3390\/diagnostics10100852","article-title":"Atherosclerosis imaging with 18F-sodium fluoride PET","volume":"10","author":"H\u00f8ilund-Carlsen","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.3233\/JAD-240206_ref26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cpet.2020.09.013","article-title":"Assessment of total-body atherosclerosis by PET\/computed tomography","volume":"16","author":"H\u00f8ilund-Carlsen","year":"2021","journal-title":"PET Clin"},{"key":"10.3233\/JAD-240206_ref27","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s00259-022-05731-x","article-title":"Parametric image generation with the uEXPLORER total-body PET\/CT system through deep learning","volume":"49","author":"Huang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240206_ref28","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.3390\/diagnostics13132254","article-title":"FDG-PET versus amyloid-PET imaging for diagnosis and response evaluation in Alzheimer\u2019s disease: Benefits and pitfalls","volume":"13","author":"H\u00f8ilund-Carlsen","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.3233\/JAD-240206_ref29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/421691a","article-title":"Toxicology rethinks its central belief","volume":"421","author":"Calabrese","year":"2003","journal-title":"Nature"},{"key":"10.3233\/JAD-240206_ref30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00259-018-4233-7","article-title":"The good rays: Let them shine!","volume":"46","author":"H\u00f8ilund-Carlsen","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240206_ref32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/15459624.2023.2268664","article-title":"Muller misled the Pugwash Conference on radiation risks","volume":"21","author":"Calabrese","year":"2024","journal-title":"J Occup Environ Hyg"},{"key":"10.3233\/JAD-240206_ref33","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-240206_ref34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-240206_ref35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: A systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240206_ref37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer\u2019s disease: Targeting \u03b2-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Transl Neurodegener"},{"key":"10.3233\/JAD-240206_ref38","doi-asserted-by":"crossref","first-page":"101996","DOI":"10.1016\/j.arr.2023.101996","article-title":"Passive Alzheimer\u2019s immunotherapy: A promising or uncertain option?","volume":"90","author":"H\u00f8ilund-Carlsen","year":"2023","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-240206_ref39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240206_ref40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240206_ref41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.3233\/JAD-240206_ref42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.trci.2017.05.003","article-title":"Ponezumab in mild-to-moderate Alzheimer\u2019s disease: Randomized phase II PET-PIB study","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240206_ref43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240206_ref44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240206_ref45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240206_ref46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: A PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240206_ref47","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240206_ref48","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240206_ref49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240206_ref50","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: Two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240206_ref51","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-240206_ref52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240206_ref53","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.3233\/JAD-240206_ref54","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JAD-240206_ref55","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: A systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"10.3233\/JAD-240206_ref56","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41582-022-00660-7","article-title":"Ventricular enlargement caused by aducanumab","volume":"18","author":"Ayton","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-240206_ref57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/snuc.2002.29269","article-title":"Guest editorial: The conception of FDG-PET imaging","volume":"32","author":"Abass","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.3233\/JAD-240206_ref58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/00004728-198308000-00003","article-title":"Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F]fluorodeoxyglucose","volume":"7","author":"Friedland","year":"1983","journal-title":"J Comput Assist Tomogr"},{"key":"10.3233\/JAD-240206_ref59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.2011.06015.x","article-title":"PET\/CT in diagnosis of dementia","volume":"1228","author":"Berti","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-240206_ref60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.semnuclmed.2020.12.008","article-title":"PET agents in dementia: An overview","volume":"51","author":"van Waarde","year":"2021","journal-title":"Semin Nucl Med"},{"key":"10.3233\/JAD-240206_ref61","doi-asserted-by":"crossref","first-page":"624330","DOI":"10.3389\/fnagi.2021.624330","article-title":"PET neuroimaging of Alzheimer\u2019s disease: Radiotracers and their utility in clinical research","volume":"13","author":"Bao","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240206_ref63","doi-asserted-by":"crossref","unstructured":"Bloudeka LM , Spackman DE , Blankenburg M , Sullivan SD (2014) Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer\u2019s disease. J Alzheimers Dis, 26, 627\u2013645.","DOI":"10.3233\/JAD-2011-110458"},{"key":"10.3233\/JAD-240206_ref64","doi-asserted-by":"crossref","first-page":"W76","DOI":"10.2214\/AJR.13.12363","article-title":"Brain FDG PET and the diagnosis of dementia","volume":"204","author":"Shivamurthy","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.3233\/JAD-240206_ref65","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1038\/s41380-023-02215-8","article-title":"The use of neuroimaging techniques in the early and differential diagnosis of dementia","volume":"28","author":"Chouliaras","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-240206_ref68","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-240206_ref69","first-page":"268","article-title":"18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer\u2019s disease","volume":"8","author":"Filippi","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240206_ref70","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JAD-130485","article-title":"Amyloid-\u03b2 positron emission tomography imaging probes: A critical review","volume":"36","author":"Kepe","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240206_ref71","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s13139-017-0484-7","article-title":"Development of tau PET imaging ligands and their utility in preclinical and clinical studies","volume":"52","author":"Choi","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240206_ref72","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-240206_ref73","doi-asserted-by":"crossref","first-page":"1356656","DOI":"10.3389\/fnagi.2024.1356656","article-title":"Seeing beyond the symptoms: Biomarkers and brain regions linked to cognitive decline in Alzheimer\u2019s disease","volume":"16","author":"Hojjati","year":"2024","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240206_ref74","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.117.200006","article-title":"Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity","volume":"59","author":"Southekal","year":"2018","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-240206_ref75","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.117.200691","article-title":"Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18","volume":"59","author":"Devous","year":"2018","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-240206_ref76","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer\u2019s disease dementia","volume":"142","author":"Pontecorvo","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JAD-240206_ref77","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240206_ref78","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1212\/WNL.0000000000007583","article-title":". A brief history of \u201cAlzheimer disease\u201d: Multiple meanings separated by a common name","volume":"92","author":"Knopman","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JAD-240206_ref79","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.3233\/JAD-240206_ref80","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/ijms25073892","article-title":"Alzheimer\u2019s amyloid hypothesis and antibody therapy: Melting glaciers?","volume":"25","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-240206_ref81","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3233\/JAD-150448","article-title":"Changes in brain volume with bapineuzumab in mild to moderate Alzheimer\u2019s disease","volume":"49","author":"Novak","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240206_ref82","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.trci.2019.05.007","article-title":"Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer\u2019s disease","volume":"5","author":"Schwarz","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-240206_ref83","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bcp.2013.11.009","article-title":"Perspective on future role of biological markers in clinical therapy trials of Alzheimer\u2019s disease: A long-range point of view beyond 2020","volume":"88","author":"Hampel","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-240206_ref84","first-page":"2044","article-title":"Aging and cerebral glucose metabolism: 18F-FDG-PET\/CT reveals distinct global and regional metabolic changes in healthy patients","volume":"13","author":"Subtirelu","year":"2023","journal-title":"Life (Basel)"},{"key":"10.3233\/JAD-240206_ref85","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2967\/jnumed.107.045385","article-title":"Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer\u2019s disease, and other dementias","volume":"49","author":"Mosconi","year":"2008","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-240206_ref86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fnagi.2019.00015","article-title":"Links between metabolic and structural changes in the brain of cognitively normal older adults: A 4-year longitudinal follow-up","volume":"11","author":"Castellano","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240206_ref87","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00259-008-1039-z","article-title":"FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer\u2019s disease","volume":"36","author":"Mosconi","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240206_ref88","doi-asserted-by":"crossref","first-page":"E1315","DOI":"10.1152\/ajpendo.00067.2014","article-title":"Glucose hypometabolism is highly localized, but lower cortical thickness and brain atrophy are widespread in cognitively normal older adults","volume":"306","author":"Nugent","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.3233\/JAD-240206_ref89","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3233\/JAD-190220","article-title":"18F-FDG is a superior indicator of cognitive performance compared to 18F-florbetapir in Alzheimer\u2019s disease and mild cognitive impairment evaluation: A global quantitative analysis","volume":"70","author":"Khosravi","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240206_ref90","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cpet.2022.03.009","article-title":"Positron emission tomography-based assessment of cognitive impairment and dementias, critical role of fluorodeoxyglucose in such settings","volume":"17","author":"Newberg","year":"2022","journal-title":"PET Clin"},{"issue":"Suppl 1","key":"10.3233\/JAD-240206_ref91","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.2967\/jnumed.121.263194","article-title":"18F-FDG PET imaging in neurodegenerative dementing disorders: Insights into subtype classification, emerging disease categories, and mixed dementia with copathologies","volume":"63","author":"Minoshima","year":"2022","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-240206_ref92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/cjn.2024.31","article-title":"PET imaging in dementia: Mini-review and Canadian perspective for clinical use","author":"Juengling","year":"2024","journal-title":"Can J Neurol Sci"},{"key":"10.3233\/JAD-240206_ref93","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer\u2019s disease","volume":"129","author":"Engler","year":"2006","journal-title":"Brain"},{"issue":"Pt A","key":"10.3233\/JAD-240206_ref94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nbd.2014.05.001","article-title":"Early detection of Alzheimer\u2019s disease using PiB and FDG PET","volume":"72","author":"Cohen","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-240206_ref95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00259-019-04564-5","article-title":"Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer\u2019s disease: Why it is time to abandon the approach","volume":"47","author":"Alavi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240206_ref96","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/RLU.0000000000004710","article-title":"FDG PET (and MRI) for monitoring immunotherapy in Alzheimer disease","volume":"48","author":"H\u00f8ilund-Carlsen","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.3233\/JAD-240206_ref98","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1093\/brain\/aww159","article-title":"Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer\u2019s disease","volume":"139","author":"Ch\u00e9telat","year":"2016","journal-title":"Brain"},{"key":"10.3233\/JAD-240206_ref99","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000478007","article-title":"Effectiveness of florbetapir pet imaging in changing patient management","volume":"44","author":"Pontecorvo","year":"2017","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-240206_ref100","doi-asserted-by":"crossref","first-page":"e0221365","DOI":"10.1371\/journal.pone.0221365","article-title":"Amyloid-\u03b2 PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer's disease diagnosis in a memory clinic","volume":"14","author":"M\u00fcller","year":"2019","journal-title":"PLoS One"},{"key":"10.3233\/JAD-240206_ref101","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3233\/JAD-190559","article-title":"Probing estrogen sulfotransferase-mediated inflammation with [11C]-PiB in the living human brain","volume":"73","author":"Surmak","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240206_ref102","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJMoa2310168","article-title":"Biomarker changes during 20 years preceding Alzheimer\u2019s disease","volume":"390","author":"Jia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240206_ref103","doi-asserted-by":"crossref","first-page":"e0285220","DOI":"10.1371\/journal.pone.0285220","article-title":"Does adding MRI and CSF-based biomarkers improve cognitive status classification based on cognitive performance questionnaires?","volume":"18","author":"Farina","year":"2023","journal-title":"PLoS One"},{"key":"10.3233\/JAD-240206_ref104","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JAD-215046","article-title":"Is Amyloid burden measured by 18F-flutemetamol PET associated with progression in clinical Alzheimer\u2019s disease?","volume":"85","author":"M\u00fcller","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240206_ref105","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/ene.14622","article-title":"\u03b2-Amyloid may accumulate in the human brain after focal bacterial infection: An 18 F-flutemetamol positron emission tomography study","volume":"28","author":"Rogne","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-240206_ref106","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-200868","article-title":"The role of amyloid-\u03b2 in white matter damage: Possible common pathogenetic mechanisms in neurodegenerative and demyelinating diseases","volume":"78","author":"Pietroboni","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240206_ref107","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13195-021-00933-1","article-title":"Amyloid PET imaging and dementias: Potential applications in detecting and quantifying early white matter damage","volume":"14","author":"Pietroboni","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240206_ref108","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-240206_ref109","doi-asserted-by":"crossref","first-page":"e200119","DOI":"10.1212\/NXG.0000000000200119","article-title":"Case of autosomal dominant Alzheimer disease with negative findings from PiB-PET examination","volume":"10","author":"Sun","year":"2023","journal-title":"Neurol Genet"},{"key":"10.3233\/JAD-240206_ref110","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s00259-011-1745-9","article-title":"The importance of appropriate partial volume correction for PET quantification in Alzheimer\u2019s disease","volume":"38","author":"Thomas","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-240206_ref111","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1002\/alz.13158","article-title":"Longitudinal amyloid and tau PET imaging in Alzheimer\u2019s disease: A systematic review of methodologies and factors affecting quantification","volume":"19","author":"Bollack","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref112","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3233\/JAD-215275","article-title":"Aducanumab (marketed as Aduhelm) approval is likely based on misinterpretation of PET imaging data","volume":"84","author":"H\u00f8ilund-Carlsen","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240206_ref113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1370\/afm.3050","article-title":"Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: A systematic review and meta-analysis","volume":"22","author":"Ebell","year":"2024","journal-title":"Ann Fam Med"},{"key":"10.3233\/JAD-240206_ref114","doi-asserted-by":"crossref","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","article-title":"Long-term effects of cholinesterase inhibitors on cognitive decline and mortality","volume":"96","author":"Xu","year":"2021","journal-title":"Neurology"},{"key":"10.3233\/JAD-240206_ref115","doi-asserted-by":"crossref","first-page":"e053012","DOI":"10.1136\/bmjopen-2021-053012","article-title":"Comparative safety and efficacy of cognitive enhancers for Alzheimer\u2019s dementia: A systematic review with individual patient data network meta-analysis","volume":"12","author":"Veroniki","year":"2022","journal-title":"BMJ Open"},{"key":"10.3233\/JAD-240206_ref118","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.pmbts.2019.07.007","article-title":"AD molecular: Imaging tau aggregates with positron emissions tomography","volume":"165","author":"Betthauser","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.3233\/JAD-240206_ref120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2967\/jnumed.117.198960","article-title":"The irony of PET tau probe specificity","volume":"59","author":"Barrio","year":"2018","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-240206_ref121","first-page":"217","article-title":"Molecular imaging: What is right and what is an illusion?","volume":"10","author":"Klunk","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref122","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.arr.2017.03.002","article-title":"In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings","volume":"36","author":"Hall","year":"2015","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-240206_ref123","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-240206_ref124","doi-asserted-by":"crossref","first-page":"e0284182","DOI":"10.1371\/journal.pone.0284182","article-title":"Comparative assessment of regional tau distribution by Tau-PET and Post-mortem neuropathology in a representative set of Alzheimer\u2019s & frontotemporal lobar degeneration patients","volume":"18","author":"Gatto","year":"2023","journal-title":"PLoS One"},{"key":"10.3233\/JAD-240206_ref125","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/alz.12356","article-title":"Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer\u2019s disease","volume":"17","author":"Ossenkoppele","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref126","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamaneurol.2023.1323","article-title":"Clinical utility of tau positron emission tomography in the diagnostic workup of patients with cognitive symptoms","volume":"80","author":"Smith","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240206_ref127","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ene.13728","article-title":"European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus","volume":"25","author":"Nobili","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-240206_ref129","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1038\/s41380-022-01685-6","article-title":"Evaluation ofstaging of amyloid deposition in cognitively unimpaired elderly aged 78-94","volume":"27","author":"Michalowska","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-240206_ref130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mds.29295","article-title":"Effect of amyloid on cognitive performance in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"38","author":"Baik","year":"2023","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-240206_ref131","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.semnuclmed.2020.12.005","article-title":"Advances in brain amyloid imaging","volume":"51","author":"Krishnadas","year":"2020","journal-title":"Sem Nucl Med"},{"key":"10.3233\/JAD-240206_ref132","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1212\/WNL.0000000000009724","article-title":"ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project","volume":"95","author":"Ebenau","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-240206_ref133","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000011415","article-title":"Alzheimer disease spectrum. Syndrome and etiology from clinical and PET imaging perspectives","volume":"96","author":"Knopman","year":"2021","journal-title":"Neurology"},{"key":"10.3233\/JAD-240206_ref134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00702-021-02449-2","article-title":"Recent update on the heterogeneity of the Alzheimer\u2019s disease spectrum","volume":"129","author":"Jellinger","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JAD-240206_ref135","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240206_ref136","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cpet.2023.08.001","article-title":"New horizons in brain PET instrumentation","volume":"19","author":"Allen","year":"2024","journal-title":"PET Clin"},{"key":"10.3233\/JAD-240206_ref137","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/diagnostics14060585","article-title":"Current trends and applications of PET\/MRI hybrid imaging in neurodegenerative diseases and normal aging","volume":"14","author":"Lee","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.3233\/JAD-240206_ref138","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12149-023-01886-1","article-title":"Visualization of small brain nuclei with a high-spatial resolution, clinically available whole-body PET scanner","volume":"38","author":"Shinohara","year":"2024","journal-title":"Ann Nucl Med"},{"key":"10.3233\/JAD-240206_ref139","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.nicl.2016.04.001","article-title":"Neural correlates of somatoform disorders from a meta-analytic perspective on neuroimaging studies","volume":"11","author":"Boeckle","year":"2016","journal-title":"Neuroimage Clin"},{"key":"10.3233\/JAD-240206_ref140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cpet.2021.08.001","article-title":"Artificial intelligence for brain molecular imaging","volume":"17","author":"Cross","year":"2022","journal-title":"PET Clin"},{"key":"10.3233\/JAD-240206_ref141","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41398-023-02528-w","article-title":"Physical symptoms and brain morphology: A population neuroimaging study in 12,286 pre-adolescents","volume":"13","author":"Est\u00e9vez-L\u00f3pez","year":"2023","journal-title":"Transl Psychiatry"},{"key":"10.3233\/JAD-240206_ref143","unstructured":"European Medicines Agency, Refusal of the marketing authorisation for Leqembi (lecanemab). https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-answers-refusal-marketing-authorisation-leqembi-lecanemab_en.pdf (2024, accessed 27 July 2024), ."},{"key":"10.3233\/JAD-240206_ref144","doi-asserted-by":"crossref","first-page":"fcab180","DOI":"10.1093\/braincomms\/fcab180","article-title":"The contribution of beta-amyloid to dementia in Lewy body diseases: A 1-year follow-up study","volume":"3","author":"Biundo","year":"2021","journal-title":"Brain Commun"},{"key":"10.3233\/JAD-240206_ref145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.dadm.2017.05.005","article-title":"Assessment of amyloid \u03b2 in pathologically confirmed frontotemporal dementia syndromes","volume":"9","author":"Tan","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-240206_ref146","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3233\/JAD-220190","article-title":"Alzheimer\u2019s disease at a crossroad: Time to part from amyloid to more promising aspects-atherosclerosis for a start","volume":"88","author":"H\u00f8ilund-Carlsen","year":"2022","journal-title":"J Alzheimers Dis"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-240206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:59:19Z","timestamp":1777370359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/JAD-240206"}},"subtitle":[],"editor":[{"given":"Paula I.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Jesus","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Daniela","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Miguel A.","family":"Pappolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Germ\u00e1n","family":"Plascencia-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Aaron A.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":136,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-240206","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}